Brief: Index Pharmaceuticals Receives FDA Clearance To Start The Phase III Study Conclude With Cobitolimod

Flerie AB

24/08/2021 08:25

Aug 24 (Reuters) - InDex Pharmaceuticals Holding AB
 INDEX.ST :
    * INDEX PHARMACEUTICALS RECEIVES FDA CLEARANCE TO START THE
PHASE
III STUDY CONCLUDE WITH COBITOLIMOD
    * STUDY WILL EVALUATE EFFICACY AND SAFETY OF FIRST-IN-CLASS
TLR9
AGONIST COBITOLIMOD

Source text for Eikon:  ID:nWkrc989yh 
Further company coverage:  INDEX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))